Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer

EJNMMI Research

Table 3 Laboratory parameters of the patient before and after ¹⁵²Tb-PSMA-617 administration

Parameters	Normal range	Units	Patient
Parameters	Normal range	Units	Before	After
Hemoglobin	8.6–12.1	mmol/L	9.0	9.5
Leukocytes	4.3–10	Gpt/L	5.9	5.1
Thrombocytes	150–400	Gpt/L	194	207
Urea	3.0–9.2	mmol/L	5.2	4.8
Creatinine	62–106	μmol/L	62.0	67.1
eGFR (MDRD)	> 60	mL/min/1.73m²	> 60	> 60
ALT	< 0.83	μmol/s/L	0.37	0.27
AST	< 0.85	μmol/s/L	0.36	0.27
GGT	0.17–1.19	μmol/s/L	0.70	0.44

eGFR (MDRD) estimated glomerular filtration rate, ALT alanine transaminase, AST aspartate transaminase, GGT gamma-glutamyl transpeptidase, Before 1 month before the PET/CT scan performed with ¹⁵²Tb-PSMA-617, After at the time of the next restaging, 6 months after the ¹⁵²Tb-PSMA-617 application